Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 23, 2025-

USPTO grants Enveric second patent allowance for next-gen mescaline derivatives - BioTuesdays

Enveric Biosciences (NASDAQ: ENVB) announced that the U.S. Patent and Trademark Office (USPTO) has granted a second Notice of Allowance for novel compounds within its next-generation, non-hallucinogenic mescaline derivatives in the EVM401 Series. According to Enveric, the second patent allowance serves to expand the company’s intellectual property assets in the treatment of mental health disorders. In a statement, Joseph Tucker, PhD, director an…